>

Exclusive | Cigna Demands FTC Retraction in Escalating Drug-Price Fight

Cigna's Response to FTC Report

Cigna has demanded the Federal Trade Commission (FTC) retract a report that alleged the company was illegally inflating drug prices. The health insurance giant has accused the FTC of relying on “flawed methodology” and “cherry-picked data” in its report. The dispute comes amid a broader debate over rising drug costs in the United States.

FTC's Allegations and Cigna's Defense

The FTC report alleged that Cigna used a “rebate scheme” to boost its revenue. Specifically, the report claimed that Cigna would pay higher prices for drugs, then negotiate large rebates from drug manufacturers. Cigna would then retain a portion of the rebates for itself, potentially leading to higher premiums for policyholders. In its response, Cigna denied these allegations. The company argued that the rebates it receives from drugmakers are used to lower premiums for policyholders, not to increase its profits. Cigna also claimed that the FTC cherry-picked data to support its claims and ignored evidence that contradicted its findings.

Escalating Drug-Price Fight

The dispute between Cigna and the FTC is part of a larger debate over rising drug costs in the United States. According to a recent study, the average cost of prescription drugs in the U.S. rose by 2.5% in 2022. This increase is significantly higher than the rate of inflation, which was 1.6% in 2022. The rising cost of drugs has placed a significant burden on consumers and healthcare providers. Many consumers are struggling to afford the medications they need, and healthcare providers are facing increasing pressure to lower costs.

Potential Impact of FTC Report

If the FTC's allegations against Cigna are proven true, the company could face significant penalties. The FTC could order Cigna to pay fines or change its business practices. The FTC's report could also lead to additional scrutiny of the pharmaceutical industry and potentially result in new regulations on drug pricing.

Questions and Answers

* What is the FTC alleging Cigna did? The FTC alleged that Cigna used a “rebate scheme” to inflate drug prices and boost its revenue. * How has Cigna responded to the FTC's allegations? Cigna has denied the FTC's allegations, arguing that the rebates it receives from drugmakers are used to lower premiums for policyholders. * What is the potential impact of the FTC's report? If the FTC's allegations against Cigna are proven true, the company could face significant penalties. The report could also lead to additional scrutiny of the pharmaceutical industry and potentially result in new regulations on drug pricing.

Conclusion

The dispute between Cigna and the FTC is part of a larger debate over rising drug costs in the United States. The outcome of this dispute could have a significant impact on the pharmaceutical industry and consumers alike.